ReviewInternational journal of molecular sciences2022
Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Migraine is a risk factor for dementia: a systematic review and meta-analysis of cohort studies.The journal of headache and pain · 2025Pooled it
- Cognitive Dysfunction in Migraine: Underlying Mechanisms and Clinical Implications.Current pain and headache reports · 2026Review
- Therapeutic strategies for Huntington's disease: current approaches and future direction.Neurodegenerative disease management · 2026Review
- Migraine and the Risk of Dementia in the General Population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Impact of migraine on quality of life and disability: a matched cross-sectional comparative study in a tertiary hospital in Malaysia.Frontiers in neurology · 2026Article
- Severity of migraine-like symptoms and its impact on executive functions in university students: a mediation model analysis.Primary health care research & development · 2025Article
- Cognitive Reserve and Its Associations with Pain, Anxiety, and Depression in Patients with Chronic Migraine: A Retrospective Study.Journal of clinical medicine · 2025Article
- Cognitive Function in Patients With Complex Regional Pain Syndrome: No Clear Impairment Found in a Select Patient Sample.European journal of pain (London, England) · 2025Article
- Migraine and cognitive dysfunction: a narrative review.The journal of headache and pain · 2024Review
- Ferroptosis as a promising targeted therapy for triple negative breast cancer.Breast cancer research and treatment · 2024Review
- Acupuncture for the Treatment of Migraine: An Overview of Systematic Reviews.Current pain and headache reports · 2023Review
- Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Migraine is a common neurological disorder impairing the quality of life of patients. The condition requires, as an acute or prophylactic line of intervention, the frequent use of drugs acting on the central nervous system (CNS). The long-term impact of these medications on cognition and neurodegeneration has never been consistently assessed. The paper reviews pharmacological migraine treatments and discusses their biological and clinical effects on the CNS. The different anti-migraine drugs show distinct profiles concerning neurodegeneration and the risk of cognitive deficits. These features should be carefully evaluated when prescribing a pharmacological treatment as many migraineurs are of scholar or working age and their performances may be affected by drug misuse. Thus, a reconsideration of therapy guidelines is warranted. Furthermore, since conflicting results have emerged in the relationship between migraine and dementia, future studies must consider present and past pharmacological regimens as potential confounding factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.